CTXR
What one share of Citius Pharmaceuticals holds
Pharmaceutical Preparations
Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products.
Citius Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.12 |
|---|---|
| Cash and investments | $0.62 |
| Debt | $11.16 |
| Book value | $2.43 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$57.24 | — | −$40.71 | $225.00 | $85.97 |
| 2017 | $0.23 | −$47.36 | $0.01 | −$36.36 | — | $65.74 |
| 2018 | $0.17 | −$29.20 | — | −$26.37 | — | $47.29 |
| 2019 | $0.11 | −$19.30 | — | −$15.42 | — | $23.46 |
| 2020 | $0.06 | −$11.20 | $0.00 | −$10.81 | — | $15.15 |
| 2021 | $0.02 | −$5.64 | $0.00 | −$5.58 | — | $22.64 |
| 2022 | $0.02 | −$5.76 | — | −$4.85 | — | $17.58 |
| 2023 | — | −$5.57 | — | −$4.80 | — | $14.29 |
| 2024 | — | −$5.97 | — | −$4.19 | — | $9.67 |
| 2025 | — | −$3.38 | — | −$2.40 | — | $3.74 |